Dr. Roberts investigates brain-wave scanning with magnetoencephalography (MEG) and works to identify biomarkers for neuropsychiatric disorders like autism. Those biomarkers are for diagnosis, prognosis, stratification, and response monitoring as well as substrate identification for targeted therapy. Putting the "bio" into biomarkers is a major emphasis of Dr. Roberts' research, for which he uses advanced diffusion magnetic resonance imaging (MRI) and edited spectroscopy.
Dr. Hartung's clinical and translational research program focuses on autosomal recessive polycystic kidney disease and other genetic kidney diseases, development of new kidney and liver imaging biomarkers, and neurocognitive outcomes in children with chronic kidney disease.
Dr. Schultz's research involves using magnetic resonance imaging to understand brain mechanisms and to create biomarkers that predict who has autism spectrum disorder (ASD), who will develop the disorder, and who will respond well to different interventions. More recently, he has developed a technology and innovation lab to exploit advances in perceptual computing, in order to develop more robust measurements of quantitative traits.
Dr. Cielo conducted clinical and translational research related to the mechanisms and effects of obstructive sleep apnea in children, with a specific focus on infant populations, children with craniofacial conditions, and the use of MRI and other imaging modalities to understand structural contributors to obstructive sleep apnea in children.